Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desaspidin SCHEMBL29613713 | 1.00 | FASN (0.51) | FASNMEN1KMT2APAK1HMGCR | |
| Desaspidin SCHEMBL28086151 | 0.90 | FASN (0.42) | FASNMEN1KMT2APAK1CYP19A1 | |
| SCHEMBL29387296 | 0.89 | FASN (0.59) | FASNMEN1KMT2APAK1HMGCR | |
| SCHEMBL30212080 | 0.85 | FASN (0.66) | FASNMEN1KMT2APAK1HMGCR | |
| SCHEMBL30212085 | 0.85 | FASN (0.66) | FASNMEN1KMT2APAK1HMGCR | |
| SCHEMBL8573383 | 0.83 | FASN (0.51) | FASNMEN1KMT2APAK1HMGCR | |
| SCHEMBL4742082 | 0.82 | FASN (0.63) | FASNPTGESALOX5 | |
| SCHEMBL155672 | 0.80 | FASN (0.48) | FASN | |
| SCHEMBL1785484 | 0.78 | FASN (0.60) | FASNPTGESALOX5PLA2G2APLA2G5 | |
| SCHEMBL4962391 | 0.76 | FASN (0.64) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150056160-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-0931542-B1 | Cosmetic composition containing phloroglucinol | OREAL (FR) | 2004-01-14 | — | — | EP | claimed |
| EP-1098641-A4 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | ST JUDE PHARMACEUTICALS INC (US) | 2003-08-27 | — | — | EP | claimed |
| EP-1098641-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | Texas Pharmaceuticals, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6054137-A | A THERAPEUTIC TREATMENT FOR STIMULATING PROLIFERATION OF HUMAN KERATINOCYTES AND FOR SKIN DISORDERS | SOCIETE L'OREAL S.A. (FR) | 2000-04-25 | — | — | US | claimed |
| WO-2000006143-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. (US) | 2000-02-10 | — | — | WO | claimed |
| US-5807898-A | ASPIDIN, DESASPIDIN, METHYLENEBISASPIDINOL | KAPADIA GOVIND J (US) | 1998-09-15 | — | — | US | claimed |
| WO-2026090318-A2 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | DEFY-Tech Labs, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108444-A1 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | DEFY TECH LABS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260081034-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | EMERJA CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260081035-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | EMERJA CORP (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025128952-A1 | MANGANESE DOPED METAL ORGANIC FRAMEWORKS AND METHODS OF MAKING AND USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-5807898-A | ASPIDIN, DESASPIDIN, METHYLENEBISASPIDINOL | KAPADIA GOVIND J (US) | 1998-09-15 | — | — | US | disclosed |
| US-5807898-A | ASPIDIN, DESASPIDIN, METHYLENEBISASPIDINOL | KAPADIA GOVIND J (US) | 1998-09-15 | — | — | US | disclosed |
| US-5684035-A | NAPHTHOQUINONES | KAPADIA GOVIND J (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0412211-A1 | Cancer therapy system | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1991-02-13 | — | — | EP | disclosed |
| US-4935450-A | Cancer therapy system for effecting oncolysis of malignant neoplasms | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| US-4724234-A | ADMINISTERING NUTRITIONAL REGIMEN AND AGENTS WHICH UNCOUPLE OXIDATIVE PHOSPHORYLATION | THERAPEUTICAL SYSTEMS CORP. (US) | 1988-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108444-A1 | ENCAPSULATION COMPOSITIONS AND METHODS FOR ENCAPSULATING ACTIVE AGENTS | LIPA, LIPC, ACACA | FASN 87/4885MEN1 3824/4885KMT2A 2567/4885 |
| US-20260081035-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | PYGB, CRH, CRY1 | FASN 2989/4885MEN1 1037/4885KMT2A 3027/4885 |
| US-20260081034-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | CRH, HCRTR1, PER2 | FASN 2471/4885MEN1 2123/4885KMT2A 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.